Key result
The abstract explores the Brain Fatigue Generator model for post-viral fatigue syndromes and mentions a pilot placebo-controlled study of a dopamine 2 receptor agonist, but reports no quantitative results.
Why the study?
Does a dopamine 2 receptor agonist improve fatigue in polio survivors with post-polio fatigue?
Does a dopamine 2 receptor agonist improve fatigue in polio survivors with post-polio fatigue?
The paper proposes a Brain Fatigue Generator model for post-viral fatigue syndromes and discusses a pilot study of a dopamine 2 receptor agonist for post-polio fatigue.
Answers are grounded in this paper and cite their sources.
Leaves open dopamine 2 agonist use for post-polio fatigue; hypothesis-generating model requires prospective trials.
Fatigue is the most commonly reported and most debilitating Post-Polio Sequelae (PPS), affecting millions of polio survivors world-wide. Post-polio fatigue is associated with: (1) subjective reports of difficulty with attention, cognition, word-finding and maintaining wakefulness; (2) clinically significant deficits on neuropsychological tests of information processing speed and attention; (3) gray and white matter hyperintensities in the reticular activating system on magnetic resonance imaging of the brain; (4) neuroendocrine evidence of impaired activation of the HPA axis. Many of these findings are identical to those documented following a variety of viral encephalitides, including acute poliovirus infection, lethargic encephalitis, Iceland Disease, myalgic encephalomyelitis, and, most recently, Chronic Fatigue Syndrome. The clinical, historic, neuropsychologic, neuroanatomic and physiologic parallels between poliovirus infection, post-polio fatigue and post-viral fatigue syndromes (PVFS) will be explored in an attempt to describe the pathophysiology of PVFS. The disinhibition of a putative Brain Fatigue Generator will be implicated as a cause of the subjective symptoms and objective signs that accompany PVFS. The results of a pilot placebo-controlled study of a dopamine 2 receptor agonist to treat post-polio fatigue will also be described.
No takes yet. Share an insight, caveat, or question.
Bruno et al. (1996) conducted a review in Post-polio fatigue and Post-Viral Fatigue Syndromes. Dopamine 2 receptor agonist vs. Placebo was evaluated. The abstract explores the Brain Fatigue Generator model for post-viral fatigue syndromes and mentions a pilot placebo-controlled study of a dopamine 2 receptor agonist, but reports no quantitative results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: